Monte Rosa Therapeutics, Inc. (GLUE)
13.78
-0.52
(-3.67%)
USD |
NASDAQ |
Aug 24, 16:00
13.77
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Enterprise Value : 590.88M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 590.88M |
| August 21, 2026 | 635.62M |
| August 20, 2026 | 676.53M |
| August 19, 2026 | 760.90M |
| August 18, 2026 | 697.84M |
| August 17, 2026 | 727.66M |
| August 14, 2026 | 737.89M |
| August 13, 2026 | 766.87M |
| August 12, 2026 | 776.24M |
| August 11, 2026 | 760.05M |
| August 10, 2026 | 765.16M |
| August 07, 2026 | 770.28M |
| August 06, 2026 | 755.79M |
| August 05, 2026 | 747.27M |
| August 04, 2026 | 787.32M |
| August 03, 2026 | 727.66M |
| July 31, 2026 | 824.82M |
| July 30, 2026 | 1.350B |
| July 29, 2026 | 1.254B |
| July 28, 2026 | 1.295B |
| July 27, 2026 | 1.340B |
| July 24, 2026 | 1.358B |
| July 23, 2026 | 1.380B |
| July 22, 2026 | 1.444B |
| July 21, 2026 | 1.431B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.418B |
| July 17, 2026 | 1.510B |
| July 16, 2026 | 1.391B |
| July 15, 2026 | 1.412B |
| July 14, 2026 | 1.416B |
| July 13, 2026 | 1.290B |
| July 10, 2026 | 1.380B |
| July 09, 2026 | 1.507B |
| July 08, 2026 | 1.467B |
| July 07, 2026 | 1.496B |
| July 06, 2026 | 1.398B |
| July 02, 2026 | 1.480B |
| July 01, 2026 | 1.464B |
| June 30, 2026 | 1.479B |
| June 29, 2026 | 1.388B |
| June 26, 2026 | 1.252B |
| June 25, 2026 | 1.199B |
| June 24, 2026 | 1.131B |
| June 23, 2026 | 1.119B |
| June 22, 2026 | 947.13M |
| June 18, 2026 | 916.77M |
| June 17, 2026 | 925.21M |
| June 16, 2026 | 870.40M |
| June 15, 2026 | 900.75M |
| June 12, 2026 | 910.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nurix Therapeutics, Inc. | 2.339B |
| Gilead Sciences, Inc. | 203.38B |
| Ironwood Pharmaceuticals, Inc. | 1.000B |
| Capricor Therapeutics, Inc. | 248.25M |
| Cue Biopharma, Inc. | 112.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.40M |
| Revenue (Quarterly) | 8.968M |
| Total Expenses (Quarterly) | 52.36M |
| EPS Diluted (Quarterly) | -0.4276 |
| Gross Profit Margin (Quarterly) | 78.69% |
| Profit Margin (Quarterly) | -483.9% |
| Earnings Yield | -13.84% |
| Normalized Earnings Yield | -13.83 |